Loading...
LLY logo

Eli Lilly and CompanyNYSE:LLY Voorraadrapport

Marktkapitalisatie US$949.7b
Prijs aandeel
US$1.07k
US$1.21k
11.9% ondergewaardeerd intrinsieke korting
1Y49.2%
7D7.8%
1D
Portefeuillewaarde
​
Bekijk

Eli Lilly and Company

NYSE:LLY Voorraadrapport

Marktkapitalisatie: US$949.7b

Eli Lilly (LLY) Aandelenoverzicht

Eli Lilly and Company ontdekt, ontwikkelt, produceert en verkoopt farmaceutische producten voor mensen in de Verenigde Staten, Europa, China en Japan. Meer informatie

Beloningen

Verhandeld tegen 24.2% onder onze schatting van de reële waarde

De winst zal naar verwachting met 16.72% per jaar groeien

De winst groeide het afgelopen jaar met 127.6%

Risicoanalyse

Hoog niveau van niet-contante inkomsten

Heeft een hoog schuldenniveau


LLY Community Fair Values

Create Narrative

See what 734 others think this stock is worth. Follow their fair value or set your own to get alerts.

Analyst Price Targets

Top Community Narratives

27.9% undervalued
2mo ago

Eli Lilly: A Pipeline-Driven Growth Story Trading 30% Below What the Business Is Actually Worth

3.2k
0
21
10.4% undervalued
6mo ago

Eli Lilly's Future Growth Driven by Tirzepatide and Favorable Market Conditions

3.9k
2
37
View all narratives

Eli Lilly and Company Concurrenten

Prijsgeschiedenis en prestaties

Overzicht van hoogtepunten, dieptepunten en veranderingen in de aandelenkoersen voor Eli Lilly
Historische aandelenkoersen
Huidige aandelenkoersUS$1,065.00
52 Week HoogtepuntUS$1,133.95
52 Week LaagUS$623.78
Bèta0.48
1 maand verandering20.48%
3 maanden verandering2.19%
1 Jaar Verandering49.22%
3 jaar verandering150.12%
5 jaar verandering433.19%
Verandering sinds IPO37,819.33%

Recent nieuws en updates

Seeking Alpha • May 19

Eli Lilly Is A Buy (Technical Analysis)

Summary Eli Lilly exhibits strong bullish technicals, with price action, momentum, and relative strength all supporting a continued uptrend. Despite an 'F' valuation grade, LLY's growth, profitability, and upward earnings revisions reinforce its investment appeal. Recent earnings beat expectations, with Q1 EPS of $8.55 and revenue of $19.8B; 2026 guidance was raised. Institutional accumulation is evident, and I would reconsider my position only if LLY closes below its 30-week EMA. Read the full article on Seeking Alpha

Recent updates

Seeking Alpha • May 19

Eli Lilly Is A Buy (Technical Analysis)

Summary Eli Lilly exhibits strong bullish technicals, with price action, momentum, and relative strength all supporting a continued uptrend. Despite an 'F' valuation grade, LLY's growth, profitability, and upward earnings revisions reinforce its investment appeal. Recent earnings beat expectations, with Q1 EPS of $8.55 and revenue of $19.8B; 2026 guidance was raised. Institutional accumulation is evident, and I would reconsider my position only if LLY closes below its 30-week EMA. Read the full article on Seeking Alpha
Narratiefupdate • May 07

LLY: Obesity Pricing Pressure And Safety Headlines Will Shape Future Franchise Economics

Analysts have raised Eli Lilly's implied fair value from $883.99 to $899.73 after several firms increased their price targets by $1 to $50, citing confidence in the obesity and diabetes pipeline, Foundayo's regulatory progress, and clarifications around recent safety concerns. Analyst Commentary Recent research on Eli Lilly reflects a mix of enthusiasm around obesity and diabetes assets and a clearer, more cautious minority that is focused on how much optimism is already reflected in the stock.
Narratiefupdate • Apr 20

LLY: Obesity And Diabetes Platform Will Support Premium Positioning Beyond 2030

Analysts have slightly raised their average price targets on Eli Lilly in recent weeks, citing supportive trial updates in obesity and diabetes, favorable comparisons to competing GLP-1 therapies, and regulatory progress that they say supports high but unchanged fair value estimates of around $1,500. Analyst Commentary Recent Street research around Eli Lilly has been active, with a cluster of price target moves, rating changes, and product specific notes that give you a clearer sense of how professionals are framing the risk and reward.
Narratiefupdate • Apr 06

LLY: Oral GLP-1 Launch And Capacity Expansion Will Drive Future Obesity Upside

Analysts have nudged Eli Lilly's price target slightly higher by $1, reflecting updated views on obesity and diabetes franchises following recent Foundayo approval commentary and comparative GLP-1 data. Analyst Commentary Recent research on Eli Lilly clusters around obesity and diabetes, pricing dynamics in GLP-1 therapies, and the implications of new product approvals and trial readouts for long term growth and valuation.
Nieuw narratief • Mar 25

Eli Lilly: A Pipeline-Driven Growth Story Trading 30% Below What the Business Is Actually Worth

Eli Lilly already runs one of the fastest-growing drug businesses on earth, and its most powerful drug is not even approved yet. WHERE THE STOCK SITS TODAY The current price is around $907 (25/03/2026).
Narratiefupdate • Mar 23

LLY: Obesity And Diabetes Franchise Strength Will Support Premium Positioning

Analysts have raised their price target for Eli Lilly to $1,500, citing updated models that reflect slightly stronger assumed revenue growth, a marginally higher profit margin profile, and continued confidence in the obesity and diabetes franchises following recent trial data and supportive sell side research. Analyst Commentary Recent research highlights a split view on Eli Lilly, with some bullish analysts leaning into the obesity and diabetes opportunity set, while at least one more cautious voice questions how much growth is already reflected in the share price.
Narratiefupdate • Mar 09

LLY: Obesity Drug Leadership And Pipeline Catalysts Will Sustain Premium Positioning

The updated analyst price target for Eli Lilly has increased to $1,490.52 from $1,429.89. Analysts highlight the obesity and GLP-1 franchise, premium valuations tied to weight loss leadership, and potential upside from pipeline and acquisition catalysts as key factors supporting this change.
Narratiefupdate • Feb 23

LLY: GLP-1 Obesity Leadership Will Drive Future Cardiometabolic And M&A Upside

Eli Lilly's analyst price targets have shifted higher, with our fair value estimate moving from $1,093.22 to $1,211.21, as analysts point to sustained GLP-1 obesity leadership, premium valuation support, and an expanding cardiometabolic pipeline as key drivers of their updated views. Analyst Commentary Recent Street research on Eli Lilly clusters around a few clear themes, with bullish analysts focusing on obesity leadership, cardiometabolic breadth, and M&A, while more cautious voices watch valuation and execution risk around the pipeline.
Narratiefupdate • Feb 08

LLY: Government Pricing Deals Will Compress Obesity Franchise Economics Going Forward

Analysts have raised their fair value estimate for Eli Lilly from US$770 to about US$884 per share, reflecting updated assumptions on long term obesity opportunities, recent price target increases across several firms, and steady expectations around margins and future P/E multiples. Analyst Commentary The latest batch of research on Eli Lilly revolves around its weight loss and cardiometabolic franchises, expectations for new product launches, and the implications of recent policy developments on pricing and access.
Analyseartikel • Feb 07

Eli Lilly and Company (NYSE:LLY) Just Released Its Yearly Earnings: Here's What Analysts Think

Investors in Eli Lilly and Company ( NYSE:LLY ) had a good week, as its shares rose 2.0% to close at US$1,058 following...
Narratiefupdate • Jan 25

LLY: Government GLP 1 Pricing Deals Will Pressure Obesity Margins

Analysts have nudged their price targets on Eli Lilly slightly higher, citing continued confidence in the obesity and GLP 1 franchise, supportive government pricing agreements, and potential upside from acquisitions and pipeline catalysts, even as some firms fine tune their models and individual targets by low single digit amounts such as Guggenheim's recent US$2 trim. Analyst Commentary Recent research on Eli Lilly has been dominated by optimism around obesity treatments and government pricing agreements, but there is also a pocket of caution that is worth paying attention to if you are thinking about valuation, execution and long term growth risk.
Narratiefupdate • Jan 11

LLY: GLP-1 Pricing Deals Will Pressure Obesity Margins Going Forward

Analysts lifted their fair value estimate for Eli Lilly from US$650 to US$770, citing higher assumed profit margins, a slightly higher discount rate, updated expectations for revenue growth and future P/E, and continued Street support related to the obesity franchise, GLP-1 pricing agreements, and pipeline catalysts. Analyst Commentary Recent Street research around Eli Lilly has been dominated by views on obesity drugs, pricing agreements with the U.S. government, and the company’s expanding pipeline.
Narratiefupdate • Dec 27

LLY: GLP-1 Pricing Deals And Policy Will Shape Future Obesity Leadership And Risks

Analysts have lifted their fair value estimate for Eli Lilly to approximately $1,093 from about $1,024, reflecting expectations for stronger long term GLP 1 driven revenue growth, expanding profit margins and sustained leadership in the obesity market, supported by recent U.S. reimbursement and pricing deals. Analyst Commentary Street research remains broadly constructive on Eli Lilly, with a series of upward price target revisions and fresh coverage initiations underscoring confidence in the durability of its GLP 1 franchise and broader innovation pipeline.
Narratiefupdate • Dec 13

LLY: Government Access Deals Will Drive Durable Obesity And Diabetes Leadership

Analysts have raised their fair value estimate for Eli Lilly shares from approximately $1,170 to about $1,430 per share, reflecting higher expected profitability and sustained leadership in the GLP 1 obesity and diabetes market, supported by recent U.S. government access deals and upcoming launches such as orforglipron. Analyst Commentary Bullish analysts continue to frame Eli Lilly as a core beneficiary of the expanding obesity and diabetes treatment market, with valuation upside tied to both higher GLP 1 penetration and a broadening metabolic pipeline.
Narratiefupdate • Nov 29

LLY: Upcoming Price Discounts And Policy Decisions Will Influence Drug Market Leadership And Risks

Eli Lilly's analyst price target has increased by approximately $21 to $1,024. Analysts cite earnings upside, expanding obesity drug opportunities, and recently announced government reimbursement agreements as key drivers of improved growth and profitability expectations.
Analyseartikel • Nov 25

Investors Appear Satisfied With Eli Lilly and Company's (NYSE:LLY) Prospects As Shares Rocket 30%

Despite an already strong run, Eli Lilly and Company ( NYSE:LLY ) shares have been powering on, with a gain of 30% in...
Narratiefupdate • Nov 21

GLP-1 drugs part of medicare

Short update, this is more bullish news about the demand for GLP-1 drugs in general spurring growth in this type of weight loss drug. Also, earnings report have showed that increase in earnings have been driven by increase in volume of GLP-1 drugs.
Narratiefupdate • Nov 15

LLY: Upcoming Drug Price Reductions and Policy Debates Will Shape Future Opportunities and Risks

The analyst price target for Eli Lilly has increased by over $80 to approximately $1,003 per share. Analysts point to accelerating revenue growth, higher profit margins, and ongoing strength in the company's obesity drug franchise as drivers of greater long-term value.
Analyseartikel • Nov 07

Eli Lilly (NYSE:LLY) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

Eli Lilly and Company's ( NYSE:LLY ) stock was strong after they recently reported robust earnings. However, we think...
Narratiefupdate • Nov 01

LLY: Upcoming Drug Launches And Global Expansion Will Shape Future Outlook

Eli Lilly’s fair value estimate has increased from $891.62 to $919.33. This reflects analysts' upward price target revisions following stronger than expected quarterly results and an improved earnings outlook.
Nieuw narratief • Sep 19

Eli Lilly's Future Growth Driven by Tirzepatide and Favorable Market Conditions

Catalysts Mounjaro/Zepbound: Lilly’s tirzepatide franchise is the engine of growth. Mounjaro (for type 2 diabetes) and Zepbound (obesity) each grew rapidly in 2024.

Rendement voor aandeelhouders

LLYUS PharmaceuticalsUS Markt
7D7.8%5.3%1.1%
1Y49.2%44.3%28.7%

Rendement versus industrie: LLY overtrof de US Pharmaceuticals industrie, die het afgelopen jaar een rendement 44.3 % opleverde.

Rendement versus markt: LLY overtrof de US markt, die het afgelopen jaar een rendement opleverde van 28.7 %.

Prijsvolatiliteit

Is LLY's price volatile compared to industry and market?
LLY volatility
LLY Average Weekly Movement5.3%
Pharmaceuticals Industry Average Movement9.9%
Market Average Movement7.2%
10% most volatile stocks in US Market16.4%
10% least volatile stocks in US Market3.1%

Stabiele aandelenkoers: LLY heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend vergeleken met de US markt.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 5% ) van LLY is het afgelopen jaar stabiel geweest.

Over het bedrijf

OpgerichtWerknemersCEOWebsite
187650,000Dave Rickswww.lilly.com

Eli Lilly and Company ontdekt, ontwikkelt, produceert en verkoopt farmaceutische producten voor mensen in de Verenigde Staten, Europa, China, Japan en internationaal. Het bedrijf biedt cardiometabolische gezondheidsproducten, waaronder Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insuline lispro, insuline lispro protamine, insuline lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 voor diabetes; Jardiance, Mounjaro en Trulicity voor type 2 diabetes; en Zepbound voor obesitas. Het bedrijf levert ook oncologische producten, zoals Cyramza voor de tweedelijnsbehandeling van maagkanker of adenocarcinoom van de gastro-oesofageale junctie; Erbitux voor colorectale kanker en hoofd-halskanker; Inluriyo voor borstkanker; Jaypirca voor chronische lymfocytaire leukemie of klein lymfocytair lymfoom; Retevmo voor de behandeling van gemetastaseerd NSCLC; TYVYT voor klassiek hodgkinlymfoom; en Verzenio voor borstkanker.

Eli Lilly and Company Samenvatting

Hoe verhouden de winst en inkomsten van Eli Lilly zich tot de beurswaarde?
LLY fundamentele statistieken
MarktkapitalisatieUS$949.70b
Inkomsten(TTM)US$25.28b
Inkomsten(TTM)US$72.25b
37.6x
Koers/Winstverhouding
13.1x
P/S-verhouding

Is LLY overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
LLY resultatenrekening (TTM)
InkomstenUS$72.25b
Kosten van inkomstenUS$12.40b
BrutowinstUS$59.85b
Overige uitgavenUS$34.57b
InkomstenUS$25.28b

Laatst gerapporteerde inkomsten

Mar 31, 2026

Volgende inkomensdatum

Aug 05, 2026

Winst per aandeel (EPS)28.35
Brutomarge82.83%
Nettowinstmarge34.99%
Schuld/Eigen Vermogen Verhouding139.0%

Hoe presteerde LLY op de lange termijn?

Bekijk historische prestaties en vergelijking

Dividenden

0.6%
Huidig dividendrendement
22%
Uitbetalingsratio

Betaalt LLY een betrouwbaar dividend?

Zie LLY dividendgeschiedenis en benchmarks
Wanneer moet je LLY kopen om een aanstaand dividend te ontvangen?
Eli Lilly dividenddata
Ex Dividend DatumMay 15 2026
Betaaldatum dividendJun 10 2026
Dagen tot Ex-dividend11 days
Dagen tot dividendbetaaldatum15 days

Betaalt LLY een betrouwbaar dividend?

Zie LLY dividendgeschiedenis en benchmarks

Bedrijfsanalyse en status van financiële gegevens

GegevensLaatst bijgewerkt (UTC-tijd)
Bedrijfsanalyse2026/05/25 12:13
Aandelenkoers aan het einde van de dag2026/05/22 00:00
Inkomsten2026/03/31
Jaarlijkse inkomsten2025/12/31

Gegevensbronnen

De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.

PakketGegevensTijdframeVoorbeeld Amerikaanse bron *
Financiële gegevens bedrijf10 jaar
  • Resultatenrekening
  • Kasstroomoverzicht
  • Balans
Consensus schattingen analisten+3 jaar
  • Financiële prognoses
  • Koersdoelen analisten
Marktprijzen30 jaar
  • Aandelenprijzen
  • Dividenden, splitsingen en acties
Eigendom10 jaar
  • Top aandeelhouders
  • Handel met voorkennis
Beheer10 jaar
  • Leiderschapsteam
  • Raad van bestuur
Belangrijkste ontwikkelingen10 jaar
  • Bedrijfsaankondigingen

* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.

Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.

Analysemodel en Snowflake

Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen over hoe je onze rapporten kunt gebruiken en tutorials op YouTube.

Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.

Industrie en sector

Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.

Bronnen van analisten

Eli Lilly and Company wordt gevolgd door 53 analisten. 28 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.

AnalistInstelling
David ToungArgus Research Company
Emily FieldBarclays
Kerry HolfordBerenberg